Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Work In Process (2024 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Work In Process for 2 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 186.83% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 186.83% year-over-year, with the annual reading at $9.4 million for FY2025, 186.83% up from the prior year.
  • Work In Process hit $9.4 million in Q4 2025 for Eton Pharmaceuticals, up from $3.3 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $9.4 million in Q4 2025 to a low of $3.3 million in Q4 2024.